LPCN News
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Zacks
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Zacks
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciencesread more...
Benzinga
Oral Testosterone Capsule Wins Canadian Approval, Shares Up
Testosterone replacement therapy has largely relied on delivery methods that come with practical tradeoffs. Injections require needles and can cause injection-site reactions, while topical gels can be messy and carry a risk of transferring testosterone to others through skin contact. An oral treatment that does not require dose titration offers another approach in a Canadian market where more than 700,000 testosterone replacement therapy prescriptions are written annually.Shares of Lipocine Inc. (NASDAQ: LPCN) are moving higher Wednesday after the company announced that Health Canada has ...
AllPennyStocks.com
Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy
Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement TherapyPR NewswireSALT LAKE CITY, Oct. 7, 2026SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a...
PR Newswire
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPR NewswireSALT LAKE CITY, Sept. 14, 2026 Study informed by encouraging exploratory efficacy findings and a...
PR Newswire
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SALT LAKE CITY, Sept. 10, 2026 SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty...
PR Newswire
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 PR Newswire SALT LAKE CITY, Aug. 4, 2026 SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty...
PR Newswire
Lipocine Appoints Michael J. Grissinger to Board of Directors
Lipocine Appoints Michael J. Grissinger to Board of Directors Lipocine Appoints Michael J. Grissinger to Board of Directors PR Newswire SALT LAKE CITY, Aug. 3, 2026 SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary...
PR Newswire
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 PR Newswire SALT LAKE CITY, June 4, 2026...
PR Newswire